Table 8.
Duration of treatment with bisphosphonates for those patients with bone metastases/lesions who had treatment stopped owing to end of planned treatment, by malignancy type and by country: data from the detailed questionnaire
| Treatment duration (%) | Total (N = 1806) | France (n = 381) | Germany (n = 516) | Italy (n = 357) | Spain (n = 306) | UK (n = 246) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ST | HM | ST | HM | ST | HM | ST | HM | ST | HM | ST | HM | |
| ≤6 months | 28 | 20 | 37 | 23 | 14 | 4 | 24 | 23 | 33 | 20 | 50 | 20 |
| 7–12 months | 21 | 22 | 19 | 29 | 17 | 7 | 19 | 16 | 30 | 28 | 26 | 16 |
| 13–24 months | 37 | 38 | 29 | 39 | 55 | 51 | 36 | 31 | 28 | 43 | 9 | 33 |
| >24 months | 14 | 16 | 13 | 4 | 14 | 39 | 18 | 23 | 10 | 9 | 13 | 27 |
| Unknown | 1 | 4 | 2 | 4 | 0 | 0 | 2 | 7 | 0 | 0 | 2 | 4 |
HM, haematological malignancy; ST, solid tumour.